MPR Weekly Dose
MPR Weekly Dose Podcast #287 — Approvals for SMA and CKD; Joenja Approval Expanded; LSD Breakthrough in Depressive Disorder; Zasocitinib in Plaque Psoriasis
13:06
Approvals for spinal muscular atrophy and chronic kidney disease; Joenja gains expanded approval in APDS; LSD derivative earns Breakthrough status to treat major depressive disorder; and zasocitinib is granted Priority Review for psoriasis.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.